Last Updated : April 9, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
dostarlimab (Jemperli)
Therapeutic Area: Endometrial cancer
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
cemiplimab (Libtayo)
Therapeutic Area: Locally advanced or metastatic NSCLC (first line)
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
Chronic lymphocytic leukemia (CLL).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic urothelial cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Iron deficiency in adult patients with heart failure
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic colorectal cancer (mCRC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Relapsed or refractory large B-cell lymphoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Generalized myasthenia gravis (gMG).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Sickle cell disease (SCD)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Transfusion-dependent β-thalassemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Hereditary Angioedema
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : April 9, 2024